Clinical Trials

Mesothelioma

NCT06097728 2026-04-02

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT05136677 2026-01-23

CheckMate 6DW

Phase 2 Completed

102 enrolled

Mesothelioma, Malignant

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

214 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

542 enrolled

Solid Tumor

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase 1 Completed

31 enrolled 20 charts

385 enrolled 17 charts 4 FDA

Metastatic Solid Tumors

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

37 enrolled 32 charts

Phase 1/2 Active not recruiting

Solid Tumor

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03918252 2025-06-26

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Phase 2 Active not recruiting

30 enrolled

Phase 2 Active not recruiting

Mesothelioma

NCT04730544 2025-06-13

NIPISAFE

96 enrolled

GastrointestinalOther solid neoplasm

Colorectal Cancer Metastatic

NCT02913313 2025-04-20

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

101 enrolled 34 charts

Broad Solid Tumor

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

1,163 enrolled 33 charts 2 FDA

Advanced or Metastatic Solid Tumors

NCT03523819 2024-09-19

A Study of CS1002 in Subjects with Advanced Solid Tumors

Phase 1 Completed

91 enrolled

Solid Tumor, Adult

NCT06514651 2024-07-23

MAQ-001 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

30 enrolled

605 enrolled 17 charts 3 FDA

Advanced Solid Tumor

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

Phase 2 Active not recruiting

Mesothelioma

NCT04300244 2024-02-29

NIPU

118 enrolled

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma, Neoplasms

NCT03461952 2024-02-22

NIMBLe

Phase 2 Terminated

4 enrolled 4 charts

Advanced Solid Tumors

NCT03728179 2024-02-20

RACIN

Phase 1 Completed

40 enrolled

Solid Tumor, Adult

NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Phase 1 Terminated

2 enrolled 14 charts

Mesothelioma

NCT05041062 2024-01-03

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Phase 2 Completed

2 enrolled 8 charts

Lung Neoplasms, Mesothelioma

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Solid Tumor

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies